PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The identification of small molecule agonists for the nuclear receptor peroxisome proliferator-activated receptor beta/delta (PPAR-beta/delta, NR1C2) has enabled the characterization of this receptor's functions in preclinical models. Subsequently, a number of small molecule agonists of PPAR-beta/delta have been progressed into clinical trials. OBJECTIVE: This review will examine the major preclinical findings that underpin the hypothesis that PPAR-beta/delta agonists may be beneficial in treating dyslipidemia and Type 2 diabetes, as well as emerging clinical data with a variety of PPAR-beta/delta agonists. METHODS: The literature concerning preclinical experiments that combine in vivo and in vitro mechanistic studies are reviewed and compared with the results of the early clinical trials. CONCLUSIONS: Thus far, the activities of the agonists seen in the clinic are broadly similar to those seen in preclinical models. However, it is still not known if PPAR-beta/delta agonists will truly be differentiated enough from current treatments to justify their use in treating dyslipidemia or Type 2 diabetes. Major challenges for the development of PPAR-beta/delta agonists exist and the path forward is as yet undefined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“The L-165041 compound is not very potent on the murine PPARβ / δ receptor [10] , and subsequently the potent and selective non-TZD PPARβ / δ agonist GW501516 was evaluated and published by Glaxo Wellcome [11] .”
BackgroundTanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306981100 · Cited by 832
PPAR : a dagger in the heart of the metabolic syndrome
Barish, G. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27955 · Cited by 641
Cheng, L., Ding, G., Qin, Q., Huang, Y., Lewis, W., He, N., Evans, R. M., Schneider, M. D., Brako, F. A., Xiao, Y., et al. (2004) · Nature Medicine · doi:10.1038/nm1116 · Cited by 453 · cited 1×
“A heart-specific knockout of PPARβ / δ in the mouse was characterized and found to exhibit intramyocellular lipid accumulation and reduced expression of lipid catabolism genes, consistent with the known role of PPARβ / δ in promoting skeletal muscle fatty acid oxidation [22] .”
BackgroundSafety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309 · cited 2×
“This is a telling statistic, since most of the molecules have not dropped out due to lack of efficacy [31] .”
BackgroundActivation of PPARδ alters lipid metabolism in db/db mice
Leibowitz, M. D., Fiévet, C., Hennuyer, N., Peinado-Onsurbe, J., Duez, H., Berger, J., Cullinan, C. A., Sparrow, C. P., Baffic, J., Berger, G. D., et al. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01554-4 · Cited by 308
PPARδ as a therapeutic target in metabolic disease
Reilly, S. M., & Lee, C.-H. (2008) · FEBS Letters · doi:10.1016/j.febslet.2007.11.040 · Cited by 164
Cited by
Omiecinski, C. J., Vanden Heuvel, J. P., Perdew, G. H., & Peters, J. M. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfq338 · Cited by 369
Hong, F., Xu, P., & Zhai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082189 · Cited by 139
Yepuru, M., Eswaraka, J., Kearbey, J. D., Barrett, C. M., Raghow, S., Veverka, K. A., Miller, D. D., Dalton, J. T., & Narayanan, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.147850 · Cited by 125
Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
P. Menendez-Gutierrez, M., Roszer, T., & Ricote, M. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436669 · Cited by 62
“PPARs are therefore important targets in the treatment of metabolic disorders [2] and are of interest for the treatment of chronic inflammatory diseases [3, 4].”
Background
Metadata
- Authors
- Billin, A. N.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2008-09-22
- Volume
- 17
- Issue
- 10
- Pages
- 1465-1471
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2097794161
- Cited by
- 57
- References
- 7
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. https://app.cochat.ai/papers/10.1517/13543784.17.10.1465
- The paper
- Billin, A. N. (2008). PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.17.10.1465
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.